Prescribed vitamin D and calcium preparations in patients treated with bone remodelling agents in primary care: A report of a pilot study

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 131-137

  Bayly, J R ^a,b,e   Hollands, R D ^c   Riordan Jones, S E ^a   Yemm, S J ^a   Brough Williams, I ^a   Thatcher, M ^a   Woodman, N M ^a   Dixon, T ^d  

^a Gloucestershire Primary and Community Care Audit Group   (United Kingdom)

^b UNIVERSITY OF DERBY   (United Kingdom)

^c Underwood Surgery   (United Kingdom)

^d JB Medical Ltd   (United Kingdom)

^e NONE   (United Kingdom)

Author keywords

Calcium; Osteoporosis; Therapeutics; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM; VITAMIN D;

ADULT; AGE; AGED; ARTICLE; AWARENESS; BONE REMODELING; CLINICAL PRACTICE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL PRACTICE; NUTRITIONAL STATUS; OSTEOPOROSIS; PHYSICIAN ATTITUDE; PILOT STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; UNITED KINGDOM; VITAMIN SUPPLEMENTATION;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PHYSICIANS, FAMILY; PILOT PROJECTS; PRESCRIPTIONS, DRUG; VITAMIN D;

EID: 30844441876     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80288     Document Type: Article

References (31)

1. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. January, 2005. (Available from www.nice.org.uk/pdf/TA087guidance.pdf [accessed 16 September 2005])
2. Osteoporosis. Clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. Royal College of Physicians and the Bone and Tooth Society of Great Britain, July, 2000. (Available from www.rcplondon.ac.uk/pubs/wp_osteo_update.htm [accessed 16 September 2005])
3. Glucocorticoid-induced osteoporosis. Royal College of Physicians (London), the Bone and Tooth Society of Great Britain, and the National Osteoporosis Society, 2003. (Available from www. rcplondon.ac.uk/pubs/books/ glucocorticoid/Glucocorticoid.pdf [accessed 16 September 2005])
4. National Institute for Clinical Excellence Falls: the assessment and prevention of falls in older people. November, 2004. (Available from www.nice.org.uk/pdf/CG021fullguideline.pdf [accessed 16 September 2005])
5. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: A national clinical guideline, 71. June, 2003. (Available from www.sign.ac.uk/pdf/sign71.pdf [accessed 16 September 2005])
6. Clinical Resource Efficiency Support Team. Guidance on the prevention and treatment of osteoporosis. March, 2001. (Available from www.crestni.org.uk/ publications/osteo.pdf [accessed 16 September 2005])
7. Department of Health. National Service Framework for Older People. March, 2001. (Available from www.dh.gov.uk/ assetRoot/04/07/12/83/04071283.pdf [accessed 16 September 2005])
8. Department of Health. Nutrition and bone health: with particular reference to calcium and vitamin D. Report on Health and Social Subjects, 49. London, Department of Health, 1998
9. Finch S, Doyle W, Lowe C et al. National diet and nutrition survey: people aged 65 years and over. London, HMSO, 1998
10. Wharton B, Bishop N. Rickets. Lancet 2003;362:1389-1400
11. Dawson Hughes B, Heaney RP, Holick HF et al. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-6
12. Heaney RP. Vitamin D: How much do we need, and how much is too much? Osteopor Int 2000;11:553-5
13. Hirani V, Primatesta P. Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population survey. Age Ageing 2005;34:485-91
14. Gallacher SJ, McQuillian C, Harkness M et al. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opin 2005;21:1355-61
15. Moniz C, Dew T, Dixon T. Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London. Curr Med Res Opin 2005;21:1891-4
16. Anderson F. Vitamin D for older people: how much, for whom and above all why? Age Ageing 2005;34:425-6
17. Grant AM, Avenell A, Campbell MK et al. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621-8
18. 3) for prevention of fractures in primary care. BMJ 2005;330:1003-9
19. Anderson FH, Smith HE, Raphael HM et al. Effect of annual intramuscular vitamin D supplementation on fracture risk in 9440 community living older people: the Wessex Fracture Prevention Trial [abstract]. J Bone Miner Res 2004;19(Suppl 1): Abstract No. 1220
20. McCloskey E, Selby P, Davies M et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004;19:728-36
21. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
22. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of vitamin D on falls: A meta-analysis. JAMA 2004;291:1999-2006
23. Cauley JA, Robbins J, Chen Z et al (2003). The effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
24. Data on file, Merck Sharp & Dohme Limited
25. Kirthisingha VA, Beresford P, Bell N et al. Vitamin D status in patients taking bisphosphonate drugs. Osteoporos Int 2005;15 (Suppl 2):S29
26. de Lusignan S, Valentin T, Chan T et al. Problems with primary care data quality: osteoporosis as an exemplar. Inform Primary Care 2004;12:147-156
27. Bayly JR, Carter GM. A primary care programme to reduce the incidence of osteoporotic fracture. Osteoporos Int 2003;14 (Suppl 4):S2
28. Brankin E, Mitchell C, Munro R on behalf of Lanarkshire Osteoporosis Service. Closing the osteoporosis gap in primary care: a secondary prevention of fracture programme. Curr Med Res Opin 2005;21:475-82
29. Pal B. Questionnaire survey of advice given to patients with fractures. BMJ 1999;318:500-01
30. Canagon S, St Clair M, Fraser K et al. Long term management of people with fragility fracture is inadequate: an audit from Mid Sussex, UK. Osteoporo Int 2000;11:538
31. Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998;57:378-9